The Efficacy of Eszopiclone 3 Mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause
Information source: Sepracor, Inc.
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Insomnia Secondary to Perimenopause or Menopause
Intervention: Eszopiclone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Sepracor, Inc.
Summary
To demonstrate improved subjective sleep in women with insomnia secondary to perimenopause or menopause following treatment with 3 mg of eszopiclone.
Clinical Details
Official title:
The Efficacy of Eszopiclone 3 Mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Minimum age: 40 Years.
Maximum age: 60 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria: Female patients with insomnia associated with perimenopausal or menopausal.
-
Exclusion Criteria:
-
Locations and Contacts
Additional Information
Related publications: Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006 Dec;108(6):1402-10.
Last updated: August 17, 2006
|
